Oxcarbazepine as monotherapy for seizure

February 5, 2019 0 By FM

Supernus Pharmaceuticals said USFDA has approved the company’s supplemental new drug application (sNDA) for the anti-seizure drug oxcarbazepine extended release.

Currently, oxcarbazepine is indicated as adjunctive therapy in the treatment of partial-onset seizures in adults and in children 6 to 17 years of age.

Oxcarbazepine (Oxtellar XR) is an oral once-daily formulation.

Supernus currently markets extended-release topiramate (Trokendi XR) for the prophylaxis of a migraine and the treatment of epilepsy besides Oxtellar XR. It is also developing several product candidates including SPN-810 for the treatment of impulsive aggression in ADHD patients, SPN-812 for the treatment of ADHD, and SPN-604 for the treatment of bipolar disorder.